Exagen Inc(XGN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.81 | Insider Own | 39.89% | Shs Outstand | 24.2M | Perf Week | -7.19% |
| Market Cap | 0.17B | Forward P/E | - | EPS next Y | 24.06% | Insider Trans | -0.21% | Shs Float | 14.6M | Perf Month | 2.95% |
| Enterprise Value | 0.17B | PEG | - | EPS next Q | -0.18 | Inst Own | 36.49% | Short Float | 6.46% | Perf Quarter | 66.35% |
| Income | -0.02B | P/S | 2.37 | EPS this Y | 30.41% | Inst Trans | -9.71% | Short Ratio | 3.11 | Perf Half Y | 124.12% |
| Sales | 0.07B | P/B | 13.8 | EPS next 5Y | 29.44% | ROA | -34.19% | Short Interest | 0.94M | Perf YTD | 14.64% |
| Book/sh | 0.5 | P/C | 6.87 | EPS past 3/5Y | 30.65% 6.84% | ROE | -113.82% | 52W High | -43.01% ($12.23) | Perf Year | -27.62% |
| Cash/sh | 1.02 | P/FCF | - | Sales past 3/5Y | 13.47% 9.66% | ROIC | -50.75% | 52W Low | 169.11% ($2.59) | Perf 3Y | 191.63% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 9.7% | Gross Margin | 58.64% | Volatility(W/M) | 5.23% 5.41% | Perf 5Y | -47.59% |
| Dividend TTM | - | EV/Sales | 2.42 | Sales Y/Y TTM | 20.83% | Oper. Margin | -18.58% | ATR (14) | 0.42 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.88 | EPS Q/Q | 37.15% | Profit Margin | -26.61% | RSI (14) | 51.4 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.18 | Sales Q/Q | 15.92% | SMA20 | -4.63% ($7.31) | Beta | 2.13 | Target Price | $9.86 |
| Payout | - | Debt/Eq | 2.26 | Earnings | 2026/8/4 | SMA50 | 17.36% ($5.94) | Rel Volume | 0.65 | Prev Close | $7.31 |
| Employees | 216 | LT Debt/Eq | 2.05 | EPS/Sales Surpr. | 32.08% 12.03% | SMA200 | 46.23% ($4.77) | Avg Volume(3M) | 0.30M | Price | $6.97 |
| IPO | 2019/9/19 | Option/Short | Yes/Yes | Trades | 2909 | Volume | 197,472 | Change | -4.65% |
Company
XGN is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Exagen is a U.S. life sciences company specializing in diagnostic testing for autoimmune rheumatic diseases. The company supplies its AVISE brand test portfolio to healthcare providers to help them identify and manage complex immune conditions at an early stage—including systemic lupus erythematosus—and focuses on precision testing services that span diagnosis, prognosis, and monitoring.
Over the past 1 year, roughly in the middle
43% below its 1-year high.
XGN has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +30.4% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +191.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 36.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
DFAC 0.00%
DFAS 0.00%
DCOR 0.00%
VTI 0.00%It ranks #4 in the industry
Based on market cap of $169M.
XGN $169M PER -
TMO $223B PER 32.5
DHR $141B PER 35.6
NTRA $47B PER -
FAQ
What kind of company is XGN?
XGN belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of XGN?
The market cap of XGN is approximately $169M, ranking 4,230 within its sector.
What is the 52-week high and low for XGN?
XGN has recorded a 52-week high of $12.23 and a low of $2.59.
